Clinical Trials
51
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
- Conditions
- Age Related Macular Degeneration (ARMD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06373731
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Barnet Dulaney Perkins Eye Center, Sun City, Arizona, United States
🇺🇸Retina Associates of Southern California, Huntington Beach, California, United States
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
- Conditions
- Mitochondrial MyopathiesMitochondrial DNA DepletionMitochondrial DNA MutationMitochondrial DiseasesMitochondrial DNA DeletionMitochondrial Complex I DeficiencyMitochondrial PathologyMitochondrial Metabolism Defect
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05162768
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
An Intermediate Size Expanded Access Protocol of Elamipretide
- Conditions
- Mitochondrial DiseasesBarth Syndrome
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Registration Number
- NCT04689360
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
- Conditions
- Age-related Macular Degeneration
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03891875
- Locations
- 🇺🇸
Associated Retina Consultants, Ltd., Peoria, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Arizona Retina & Vitreous Consultants, Phoenix, Arizona, United States
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
- Conditions
- Primary Mitochondrial Myopathy
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT03323749
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next